These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 3305382

  • 1. Effect of various disease states on theophylline plasma levels and on pulmonary function in patients with chronic airway obstruction treated with a sustained release theophylline preparation.
    Dal Negro R, Turco P, Pomari C, Monici-Preti P.
    Int J Clin Pharmacol Ther Toxicol; 1987 Jul; 25(7):401-5. PubMed ID: 3305382
    [Abstract] [Full Text] [Related]

  • 2. Serum theophylline concentrations and pulmonary function tests after administration of two sustained-release formulations containing theophylline in patients affected by chronic obstructive lung disease.
    Fontana G, Cresci F, Lo Sapio P, Panuccio P.
    Int J Clin Pharmacol Res; 1987 Jul; 7(5):351-6. PubMed ID: 3667008
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of standard- and sustained-release theophylline tablets in patients with chronic obstructive pulmonary disease.
    Dasta J, Mirtallo JM, Altman M.
    Am J Hosp Pharm; 1979 May; 36(5):613-7. PubMed ID: 453214
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment of chronic obstructive respiratory disease with a new purified theophylline preparation in delayed-action form].
    Kaik G.
    Wien Med Wochenschr; 1984 Apr 15; 134(7):163-9. PubMed ID: 6741156
    [Abstract] [Full Text] [Related]

  • 8. [Clinical effectiveness of a new preparation of sustained-release theophylline].
    Corrias A, Pelosi U, Corona GB, Burrai P, Corda R.
    Pediatr Med Chir; 1989 Apr 15; 11(5):537-9. PubMed ID: 2631061
    [Abstract] [Full Text] [Related]

  • 9. The combined effect of theophylline and terbutaline in patients with chronic obstructive airway diseases.
    Lamont H, van der Straeten M, Pauwels R, Moerman E, Bogaert M.
    Eur J Respir Dis; 1982 Jan 15; 63(1):13-22. PubMed ID: 7040097
    [Abstract] [Full Text] [Related]

  • 10. Slow release theophylline in patients with airways obstruction with particular reference to the effects of food upon serum levels.
    Thompson PJ, Kemp MW, McAllister WA, Turner-Warwick M.
    Br J Dis Chest; 1983 Jul 15; 77(3):293-8. PubMed ID: 6351891
    [Abstract] [Full Text] [Related]

  • 11. Effect of theophylline on cortisol plasma concentrations in patients with chronic obstructive pulmonary disease.
    Gimeno F, Steenhuis EJ, Jonkman JH.
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr 15; 28(4):139-43. PubMed ID: 2187001
    [Abstract] [Full Text] [Related]

  • 12. Role of theophyllines in severe chronic obstructive pulmonary disease.
    McNicholas WT, Mulloy E.
    Postgrad Med J; 1991 Apr 15; 67 Suppl 4():S30-3. PubMed ID: 1758832
    [Abstract] [Full Text] [Related]

  • 13. Serum theophylline and ventilatory function in chronic obstructive lung disease. Comparison between two slow-release formulations of theophylline.
    Tantucci C, Grassi V, Verdecchia P, Cornelli U, Sorbini CA.
    Int J Clin Pharmacol Ther Toxicol; 1985 Oct 15; 23(10):560-4. PubMed ID: 3905630
    [Abstract] [Full Text] [Related]

  • 14. Theophylline: biochemical pharmacology and pharmacokinetics.
    Trembath PW, Boobis SW, Richens A.
    J Int Med Res; 1979 Oct 15; 7 Suppl 1():4-15. PubMed ID: 220119
    [Abstract] [Full Text] [Related]

  • 15. Combined administration of controlled release theophylline and ranitidine: a 53-day controlled survey in patients with chronic obstructive lung disease (COLD) and peptic disease.
    Dal Negro R, Turco P, Pomari C, Trevisan F, De Conti F, Cordaro CI.
    Br J Clin Pract; 1987 Nov 15; 41(11):1004-8. PubMed ID: 3504314
    [No Abstract] [Full Text] [Related]

  • 16. [Therapy of obstructive respiratory tract diseases with pure theophylline retard].
    Arens PJ.
    Med Klin Prax; 1982 Aug 27; 77(18):48-53, 67. PubMed ID: 6752679
    [Abstract] [Full Text] [Related]

  • 17. [Results of a serum concentration-oriented dosage of a theophylline depot preparation in ambulatory patients with chronic obstructive lung disease].
    Harder S, Staib AH, Stauder J.
    Prax Klin Pneumol; 1985 Jun 27; 39(6):193-6. PubMed ID: 4022931
    [No Abstract] [Full Text] [Related]

  • 18. Long-term therapy with sustained-release theophylline.
    Myhre KI, Arnulf V, Walstad RA.
    Pharmatherapeutica; 1985 Jun 27; 4(2):92-7. PubMed ID: 3903782
    [Abstract] [Full Text] [Related]

  • 19. [Optimizing therapy with theophylline preparations in obstructive ventilation disorders. 3. Prediction of theophylline clearance with a simple pharmacokinetic method and comparison of bioavailability of various theophylline retard preparations].
    Ranke C, Schmidt G, Oellerich M, Sybrecht GW.
    Prax Klin Pneumol; 1983 Mar 27; 37(3):99-108. PubMed ID: 6856564
    [No Abstract] [Full Text] [Related]

  • 20. Theophylline binding to plasma proteins in patients with chronic obstructive pulmonary disease.
    Calandre EP, Pérez de la Cruz A, Alferez NP, Moreno Carretero E, Hinojosa R, Vázquez Mata G.
    Int J Clin Pharmacol Res; 1986 Mar 27; 6(5):397-401. PubMed ID: 3781702
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.